Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591352 | 0.82 | MET (0.45) | METKDRRETKITPDGFRA | |
| SCHEMBL31007086 | 0.82 | MET (0.47) | METKDRRETKITPDGFRA | |
| SCHEMBL25362099 | 0.82 | MET (0.48) | METKDRRETKITPDGFRA | |
| SCHEMBL2591029 | 0.80 | MET (0.39) | METKDR | |
| SCHEMBL27929011 | 0.78 | MEN1 (0.46) | METKDRMAP4K4 | |
| SCHEMBL12384866 | 0.77 | MET (0.47) | METKDRRETKITPDGFRA | |
| SCHEMBL31007081 | 0.77 | MET (0.39) | METKDRKITFLT3ROCK2 | |
| SCHEMBL30495857 | 0.74 | HSPB1 (0.49) | METKDR | |
| SCHEMBL1137074 | 0.74 | HSPB1 (0.49) | METKDR | |
| SCHEMBL29453851 | 0.73 | FGFR2 (0.38) | METKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569319-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | Deciphera Pharmaceuticals, LLS (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2563773-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | Deciphera Pharmaceuticals, LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120172382-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011139891-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172382-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885KDR 2384/4885RET 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.